-
Product Insights
Diabetic Retinopathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Diabetic Retinopathy Clinical Trial Report Overview A total of 818 diabetic retinopathy clinical trials were conducted as of October 2024. The diabetic retinopathy clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North America · ...
-
Product Insights
Diabetic Retinopathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. The Diabetic Retinopathy drugs in development market research report provide comprehensive information on...
-
Product Insights
Diabetic Macular Edema - Drugs In Development, 2024
Empower your strategies with our Diabetic Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if left untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market...
-
Product Insights
Diabetic Foot Ulcers - Drugs In Development, 2024
Empower your strategies with our Diabetic Foot Ulcers – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic foot ulcers are sores that occur on the feet of people with type 1 and type 2 diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg; pain; walking with difficulty; black, blue, or red discoloration of the feet; cold feet; and fever, skin redness, or swelling, or other signs of infection. The predisposing factors include diabetic...
-
Product Insights
Diabetic Nephropathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Nephropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic nephropathy is damage to the kidney occurring due to diabetes. It is characterized by albuminuria, a reduction in glomerular filtration rate (GFR), and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels, and smoking. This condition is managed by medication and dietary modification. The Diabetic Nephropathy drugs in development market research report provide comprehensive information on the...
-
Product Insights
Diabetic Neuropathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain. Predisposing factors include obesity, hypertension, high lipid and sugar levels, and smoking. It may be managed by medication and dietary modification. The Diabetic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Diabetic Peripheral Neuropathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet; pain or discomfort in the feet or legs, including prickly, sharp pain or burning feet; muscle weakness and loss of muscle tone in the feet and lower...
-
Product Insights
Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024
Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark...
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2024
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions. Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula. The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development...
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.